Total Payments
$65,346
2024 Payments
$1,856
Companies
26
Transactions
140
Medicare Patients
1,457
Medicare Billing
$185,557
Payment Breakdown by Category
Consulting$31,448 (48.1%)
Travel$13,760 (21.1%)
Other$12,107 (18.5%)
Food & Beverage$5,719 (8.8%)
Research$2,145 (3.3%)
Education$165.98 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $31,448 | 25 | 48.1% |
| Travel and Lodging | $13,760 | 28 | 21.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $11,107 | 11 | 17.0% |
| Food and Beverage | $5,719 | 63 | 8.8% |
| Unspecified | $2,145 | 8 | 3.3% |
| Honoraria | $625.00 | 1 | 1.0% |
| Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program | $375.00 | 1 | 0.6% |
| Education | $165.98 | 3 | 0.3% |
Payments by Type
General
$63,201
132 transactions
Research
$2,145
8 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Veloxis Pharmaceuticals, Inc. | $47,784 | 64 | $0 (2024) |
| Otsuka America Pharmaceutical, Inc. | $5,423 | 12 | $0 (2022) |
| Mallinckrodt Enterprises LLC | $4,015 | 8 | $0 (2019) |
| Mylan Inc. | $1,625 | 3 | $0 (2024) |
| Akorn, Inc. | $1,000 | 2 | $0 (2019) |
| Zydus Pharmaceuticals (USA) Inc. | $1,000 | 2 | $0 (2020) |
| Novartis Pharmaceuticals Corporation | $790.41 | 8 | $0 (2023) |
| ACCORD HEALTHCARE, INC. | $779.22 | 2 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $658.61 | 9 | $0 (2023) |
| Amneal Pharmaceuticals LLC | $500.00 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,856 | 9 | ACCORD HEALTHCARE, INC. ($500.00) |
| 2023 | $650.68 | 8 | Alexion Pharmaceuticals, Inc. ($257.47) |
| 2022 | $1,790 | 11 | Mylan Inc. ($750.00) |
| 2021 | $19,875 | 23 | Veloxis Pharmaceuticals, Inc. ($19,599) |
| 2020 | $9,169 | 22 | Veloxis Pharmaceuticals, Inc. ($8,273) |
| 2019 | $9,546 | 21 | Veloxis Pharmaceuticals, Inc. ($6,263) |
| 2018 | $3,723 | 14 | Veloxis Pharmaceuticals, Inc. ($2,910) |
| 2017 | $18,735 | 32 | Veloxis Pharmaceuticals, Inc. ($10,326) |
All Payment Transactions
140 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/12/2024 | SANOFI-AVENTIS U.S. LLC | THYMOGLOBULIN (Biological) | Food and Beverage | In-kind items and services | $65.97 | General |
| Category: Oncology | ||||||
| 10/08/2024 | SANOFI-AVENTIS U.S. LLC | THYMOGLOBULIN (Biological) | Food and Beverage | In-kind items and services | $142.76 | General |
| Category: Oncology | ||||||
| 09/05/2024 | Veloxis Pharmaceuticals, Inc. | ENVARSUS (Drug) | Food and Beverage | In-kind items and services | $82.20 | General |
| Category: TRANSPLANTATION | ||||||
| 07/09/2024 | Merck Sharp & Dohme LLC | PREVYMIS (Drug) | Food and Beverage | In-kind items and services | $26.09 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 01/24/2024 | Amneal Pharmaceuticals LLC | MYCOPHENOLATE MOFETIL (Drug) | Consulting Fee | In-kind items and services | $500.00 | General |
| Category: INTERNAL MEDICINE | ||||||
| 01/24/2024 | Mylan Inc. | MYCOPHENOLATE MOFETIL (Drug) | — | Cash or cash equivalent | $500.00 | Research |
| Study: Mycophenolate Pregnancy Exposure Registry • Category: Organ Transplants | ||||||
| 01/24/2024 | ACCORD HEALTHCARE, INC. | MYCOPHENOLATE MOFETIL (Drug) | — | Cash or cash equivalent | $500.00 | Research |
| Study: MYCOPHENOLATE PREGNANCY EXPOSURE REGISTRY • Category: Oncology | ||||||
| 01/24/2024 | Apotex Inc. | MYCOPHENOLIC ACID (Drug), MYCOPHENOLIC ACID | — | Cash or cash equivalent | $21.74 | Research |
| Study: Mycophenolate Pregnancy Exposure Registry • Category: Immunosuppressive agents | ||||||
| 01/24/2024 | Hikma Pharmaceuticals USA | Mycophenolate Mofetil (Drug) | Consulting Fee | Cash or cash equivalent | $17.24 | General |
| Category: Rheumatology | ||||||
| 10/25/2023 | Amgen Inc. | Parsabiv (Drug) | Food and Beverage | In-kind items and services | $103.67 | General |
| Category: Nephrology | ||||||
| 08/03/2023 | Alexion Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $113.42 | General |
| 06/22/2023 | Alexion Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $22.45 | General |
| 06/12/2023 | Veloxis Pharmaceuticals, Inc. | — | Education | In-kind items and services | $80.99 | General |
| 06/04/2023 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $57.79 | General |
| 06/03/2023 | Calliditas Therapeutics US Inc. | TARPEYO (Drug) | Food and Beverage | In-kind items and services | $25.64 | General |
| Category: Nephrology | ||||||
| 05/03/2023 | Alexion Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $121.60 | General |
| 04/20/2023 | Calliditas Therapeutics US Inc. | TARPEYO (Drug) | Food and Beverage | In-kind items and services | $125.12 | General |
| Category: Nephrology | ||||||
| 12/08/2022 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $83.24 | General |
| Category: NEPHROLOGY | ||||||
| 11/18/2022 | Alexion Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $22.38 | General |
| 11/17/2022 | Veloxis Pharmaceuticals, Inc. | Envarsus (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Immunosuppresant | ||||||
| 09/14/2022 | Mylan Inc. | — | — | Cash or cash equivalent | $750.00 | Research |
| Study: Mycophenolate Pregnancy Exposure Registry | ||||||
| 09/14/2022 | ACCORD HEALTHCARE, INC. | MYCOPHENOLATE MOFETIL (Drug) | — | Cash or cash equivalent | $279.22 | Research |
| Study: MYCOPHENOLATE PREGNANCY EXPOSURE REGISTRY • Category: Oncology | ||||||
| 09/14/2022 | Teva Pharmaceuticals USA, Inc. | MYCOPHENOLATE MOFETIL (Drug) | — | Cash or cash equivalent | $44.93 | Research |
| Study: Mycophenolate Pregnancy Exposure Registry • Category: Oncology | ||||||
| 09/14/2022 | Sandoz Inc. | MYCOPHENOLATE MOFETIL (Drug) | Consulting Fee | Cash or cash equivalent | $41.81 | General |
| Category: IMMUNOLOGY | ||||||
| 08/25/2022 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $87.08 | General |
| Category: Rare Disease | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Mycophenolate Pregnancy Exposure Registry | Mylan Inc. | $1,250 | 2 |
| MYCOPHENOLATE PREGNANCY EXPOSURE REGISTRY | ACCORD HEALTHCARE, INC. | $779.22 | 2 |
| Mycophenolate Pregnancy Exposure Registry | Teva Pharmaceuticals USA, Inc. | $44.93 | 1 |
| Mycophenolate REMS | Teva Pharmaceuticals USA, Inc. | $31.25 | 1 |
| Mycophenolate Pregnancy Exposure Registry | Apotex Inc. | $21.74 | 1 |
| Mycopheonolate REMS | Teva Pharmaceuticals USA, Inc. | $17.86 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 339 | 636 | $157,590 | $48,821 |
| 2022 | 10 | 339 | 615 | $149,707 | $43,794 |
| 2021 | 9 | 348 | 560 | $135,141 | $43,142 |
| 2020 | 9 | 431 | 688 | $153,763 | $49,800 |
Total Patients
1,457
Total Services
2,499
Medicare Billing
$185,557
Procedure Codes
39
All Medicare Procedures & Services
39 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 95 | 269 | $45,735 | $17,093 | 37.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 76 | 145 | $43,457 | $10,080 | 23.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 34 | 58 | $17,406 | $5,474 | 31.4% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 49 | 50 | $15,432 | $5,151 | 33.4% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 21 | 39 | $9,737 | $3,732 | 38.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 24 | 30 | $12,696 | $3,016 | 23.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 20 | 20 | $8,812 | $2,649 | 30.1% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 20 | 25 | $4,315 | $1,627 | 37.7% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 92 | 242 | $40,122 | $13,499 | 33.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 94 | 171 | $52,007 | $12,285 | 23.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 37 | 63 | $19,159 | $6,112 | 31.9% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 22 | 22 | $10,166 | $3,471 | 34.1% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 12 | 28 | $6,658 | $2,321 | 34.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 15 | 18 | $7,650 | $1,863 | 24.3% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 14 | 15 | $4,698 | $1,640 | 34.9% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 14 | 15 | $3,491 | $1,242 | 35.6% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 15 | 15 | $2,505 | $846.39 | 33.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 13 | 14 | $3,009 | $466.70 | 15.5% |
| 81000 | Manual urinalysis test with examination using microscope, non-automated | Office | 2022 | 11 | 12 | $242.00 | $47.72 | 19.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 96 | 151 | $40,583 | $11,112 | 27.4% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 63 | 139 | $23,488 | $8,205 | 34.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 32 | 63 | $15,417 | $5,344 | 34.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 39 | 59 | $15,739 | $5,138 | 32.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 30 | 45 | $16,085 | $5,108 | 31.8% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 26 | 28 | $13,244 | $4,594 | 34.7% |
About Dr. Reginald Gohh, MD
Dr. Reginald Gohh, MD is a Nephrology healthcare provider based in Riverside, Rhode Island. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/20/2006. The National Provider Identifier (NPI) number assigned to this provider is 1063466282.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Reginald Gohh, MD has received a total of $65,346 in payments from pharmaceutical and medical device companies, with $1,856 received in 2024. These payments were reported across 140 transactions from 26 companies. The most common payment nature is "Consulting Fee" ($31,448).
As a Medicare-enrolled provider, Gohh has provided services to 1,457 Medicare beneficiaries, totaling 2,499 services with total Medicare billing of $185,557. Data is available for 4 years (2020–2023), covering 39 distinct procedure/service records.
Ad
Practice Information
- Specialty Nephrology
- Location Riverside, RI
- Active Since 05/20/2006
- Last Updated 02/08/2019
- Taxonomy Code 207RN0300X
- Entity Type Individual
- NPI Number 1063466282
Products in Payments
- Envarsus (Drug) $34,385
- Envarsus XR (Drug) $10,326
- ACTHAR (Biological) $4,015
- TOLVAPTAN (Drug) $3,976
- Envarsus XR (SP) (Drug) $2,910
- MYCOPHENOLATE MOFETIL (Drug) $1,900
- Mycophenolate Mofetil (Drug) $995.84
- ILARIS (Biological) $386.00
- JYNARQUE (Drug) $303.26
- ZORTRESS (Drug) $296.66
- THYMOGLOBULIN (Biological) $208.73
- TARPEYO (Drug) $150.76
- LOKELMA (Drug) $126.19
- Veltassa (Drug) $122.74
- FARXIGA (Drug) $117.89
- Kerendia (Drug) $117.39
- LIVTENCITY (Drug) $114.30
- Antiretroviral Pregnancy Registry (Device) $107.33
- Parsabiv (Drug) $103.67
- NULOJIX (Biological) $100.91
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Nephrology Doctors in Riverside
Douglas Shemin, Md, MD
Nephrology — Payments: $36,310
Nephrology $36,310
Dr. Ankur Shah, M.d, M.D
Nephrology — Payments: $26,029
Nephrology $26,029
Joseph Lee, M.d, M.D
Nephrology — Payments: $18,723
Nephrology $18,723
Dr. Jie Tang, Md, Ms, Mph, MD, MS, MPH
Nephrology — Payments: $16,418
Nephrology $16,418
Dr. Dalia Zaky Dawoud, Md, MD
Nephrology — Payments: $11,089
Nephrology $11,089
Salam Ishak, M.d, M.D
Nephrology — Payments: $5,994
Nephrology $5,994